Iron Isomaltoside

Iron Isomaltoside is a scientifically advanced intravenous iron replacement therapy developed for the effective treatment of iron deficiency anemia. Unlike conventional iron salts, it is a carbohydrate-based iron (III) complex, designed to provide high stability, safety, and excellent patient tolerability. The formulation is colourless, odourless, and non-hygroscopic, avoiding metallic taste and moisture sensitivity associated with traditional iron preparations. As a leading API manufacturer, WBCIL adheres to stringent cGMP and ISO quality systems, supported by manufacturing expertise since 1962. This ensures consistent potency, purity, and safety across all production batches. Key Therapeutic Advantages: • High-dose iron delivery for rapid correction of iron deficiency • Controlled iron release minimizing adverse reactions • Reduced number of infusions compared to conventional IV iron therapies • Improved patient compliance and clinical outcomes WBCIL Product Highlights: • Patent held by WBCIL on Iron Isomaltoside • Manufactured under strict cGMP conditions • Low incidence of hypersensitivity reactions • Sameness study completed with the innovator product • Compliant with Indian Pharmacopoeia (IP) • Supported by COPP and Written Confirmation (WC) Applications in Medical Fields: • Iron Deficiency Anemia Treatment • Chronic Kidney Disease • Rapid Iron Replenishment • Postpartum Anemia • Chronic Heart Failure • Inflammatory Bowel Disease